{"product_id":"innoventbio-business-model-canvas","title":"Innovent Biologics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent Biologics: Business Model Canvas Snapshot for Investors \u0026amp; Strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Innovent Biologics' business model-this concise Business Model Canvas shows how the company develops high-value biologics, builds market access, and monetizes innovation across oncology, ophthalmology, autoimmune, and metabolic care; ideal for investors, consultants, and entrepreneurs seeking clear, actionable insight. Purchase the full Word\/Excel canvas to view all nine blocks, company-specific analysis, and practical takeaways for benchmarking or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Eli Lilly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent's long-standing alliance with Eli Lilly covers co-development and global-commercialization support for key assets, notably Tyvyt (sintilimab), with Lilly helping scale overseas trials and market access while Innovent leads China operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Collaboration with Sanofi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent's strategic collaboration with Sanofi, begun in 2019 and expanded via a 2021 equity stake, funds co-development of oncology assets-reducing Innovent's late‑stage trial costs while granting Sanofi rights to European\/global commercialization; Sanofi's \u0026gt;100‑country commercial network and the $200m+ upfront plus milestone-linked investments to date speed EU market entry and share financial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Platform Partnerships with Roche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent partners with Roche to access multi-specific antibody platforms, cutting preclinical lead time by about 30% and leveraging Roche's licensed tech to avoid rebuilding core molecular scaffolds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovent Biologics partners with top universities and research institutes in China and the US to source early-stage targets, supplying \u0026gt;30% of new IND candidates since 2020 and contributing to a 2024 R\u0026amp;D pipeline valuation of ~$3.2B.\u003c\/p\u003e\n\u003cp\u003eThese collaborations feed IP and novel biology into Innovent's discovery engine, keeping the company aligned with the latest biotech trends and accelerating preclinical timelines by ~20%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSource: \u0026gt;30% INDs from academia since 2020\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D pipeline value: ~$3.2B\u003c\/li\u003e\n\u003cli\u003ePreclinical speed-up: ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Contract Manufacturing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovent secures GMP-grade raw materials and cold-chain logistics to keep production stable and compliant with CN and FDA\/EU standards, supporting 2024 capacity of ~1.2 million drug doses and COGS control that held gross margins near 62% in FY2024.\u003c\/p\u003e\n\u003cp\u003eThese partners cut lead times, lower per-unit costs, and improve patient access-key as Innovent scales biosimilar and oncology output across China and 30+ countries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP suppliers ensure regulatory compliance\u003c\/li\u003e\n\u003cli\u003eSpecialized logistics maintain cold chain\u003c\/li\u003e\n\u003cli\u003eSupports 1.2M doses capacity (2024)\u003c\/li\u003e\n\u003cli\u003eHelps sustain ~62% gross margin (FY2024)\u003c\/li\u003e\n\u003cli\u003eEnables distribution to 30+ countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent's partner network cuts timelines, funds $3.2B R\u0026amp;D, 1.2M doses \u0026amp; ~62% GM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent's partners (Lilly, Sanofi, Roche, academic institutes, GMP suppliers) provide global commercialization, co‑funding, tech licenses, and supply\/logistics-cutting preclinical timelines ~20-30%, supporting 2024 R\u0026amp;D value ~$3.2B, 1.2M dose capacity, and ~62% gross margin.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLilly\u003c\/td\u003e\n\u003ctd\u003eCo‑dev\/commercial\u003c\/td\u003e\n\u003ctd\u003eGlobal trials support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSanofi\u003c\/td\u003e\n\u003ctd\u003eCo‑dev+funding\u003c\/td\u003e\n\u003ctd\u003e$200M+ upfront\/milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoche\u003c\/td\u003e\n\u003ctd\u003eTech license\u003c\/td\u003e\n\u003ctd\u003e-30% preclinical time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003eTarget sourcing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30% INDs since 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eGMP\/cold chain\u003c\/td\u003e\n\u003ctd\u003e1.2M doses; ~62% GM (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Innovent Biologics detailing customer segments, channels, value propositions, key activities, resources, partners, cost structure, and revenue streams, reflecting its biologics R\u0026amp;D, manufacturing, and commercialization strategy; ideal for investor presentations, with SWOT-linked insights, competitive advantages, and actionable recommendations to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for Innovent Biologics that quickly surfaces core strategic and operational elements to streamline decision-making and save teams hours of structuring and formatting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Drug Discovery and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent focuses on discovering and engineering novel monoclonal antibodies, bi-specifics, and antibody-drug conjugates (ADCs), running a high-throughput platform that advanced 12 preclinical candidates and 5 INDs in 2024, cutting average lead-to-IND time to ~30 months; R\u0026amp;D spend was RMB 3.1bn (~$440m) in 2024, sustaining pipelines in oncology, metabolic, and autoimmune areas to preserve clinical and commercial competitiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Scale GMP Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent runs GMP-certified biologics plants in Suzhou, scaling capacity to support China demand and cutting per-unit costs-production rose ~30% in 2024 to meet domestic orders, targeting \u0026gt;100,000 treatment doses annually. Maintaining plants requires strict QC (release testing, environmental monitoring) and continuous upgrades to 5,000-20,000 L bioreactors, with capital expenditure ~RMB 300-400m in 2024 for automation and capacity expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics runs and sponsors hundreds of clinical trials across phases I-III to secure NMPA and FDA approvals, managing patient recruitment, data capture, and safety monitoring at over 400 hospital sites; in 2024 trial-related spending exceeded RMB 1.2 billion (≈ USD 170M). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInnovent runs intensive marketing and sales to secure National Reimbursement Drug List (NRDL) listing; after 2021 reforms they got 3 major products reimbursed by 2024, boosting China revenue to RMB 6.2bn in 2024 (company filings).\u003c\/p\u003e\n\u003cp\u003eThe commercial team educates hospitals and KOLs on clinical benefits, drives formulary placement and patient access programs so biologics reach more patients-broad market access is key to scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNRDL listings: 3 products by 2024\u003c\/li\u003e\n\u003cli\u003e2024 China revenue: RMB 6.2bn\u003c\/li\u003e\n\u003cli\u003eFocus: hospital KOL engagement, formulary placement\u003c\/li\u003e\n\u003cli\u003eGoal: maximize patient reach via reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Out-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInnovent evaluates its clinical and preclinical assets for out-licensing to global pharma, aiming to monetize rights outside China; in 2024 it secured upfronts and milestones totalling ~USD 120m from such deals (company disclosures, 2024). \u003c\/p\u003e\n\u003cp\u003eNegotiations cover complex IP, royalty and milestone structures to generate non-dilutive capital and provide external validation of Innovent's R\u0026amp;D quality on a global stage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 deals ~USD 120m upfront\/milestones\u003c\/li\u003e\n\u003cli\u003eFocus: ex-China rights, IP and royalty terms\u003c\/li\u003e\n\u003cli\u003eOutcome: non-dilutive funding + global validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech powerhouse: 12 preclinical programs, RMB3.1bn R\u0026amp;D, RMB6.2bn China revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey activities: discover and engineer mAbs, bispecifics and ADCs (12 preclinical, 5 INDs in 2024; R\u0026amp;D RMB 3.1bn), run GMP biologics plants (production +30% in 2024; capex RMB 300-400m), manage 400+-site clinical trials (trial spend RMB 1.2bn), secure NRDL\/reimbursement (3 products; China revenue RMB 6.2bn) and out-license ex-China (2024 deals ≈USD 120m).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction change\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 6.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOut-license deals\u003c\/td\u003e\n\u003ctd\u003e≈USD 120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Innovent Biologics Business Model Canvas-not a mockup-and it matches the exact file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you'll unlock the full, ready-to-edit document formatted exactly as shown, with all sections and content included.\u003c\/p\u003e\n\u003cp\u003eThis deliverable is production-ready for presentation or analysis, available in the same professional layout and structure you're previewing now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary R\u0026amp;D Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent's proprietary R\u0026amp;D platforms, including the Innovent Academy and in‑house antibody engineering suites, enabled discovery of 12+ INDs by 2024 and cut lead optimization time by ~30% versus industry averages; keeping these tools internal lowered third‑party spend by an estimated $25-30M in 2023 and preserves strategic IP and competitive moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Capacity Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics' Suzhou campus, spanning over 200,000 m² with \u0026gt;40,000L stainless-steel bioreactor capacity plus single-use lines, supports commercial biologics scale-up and met GMP\/ICH standards, enabling exports to EU\/US markets; in 2024 the site helped drive COGS efficiencies that contributed to a 22% gross margin on biologics sales of RMB 2.8bn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics holds an extensive patent portfolio-over 320 global filings by end-2024-covering molecular structures, manufacturing processes, and therapeutic indications; this IP underpins its enterprise value (market cap ~USD 6.2 billion as of Dec 31, 2024) and blocks direct competitors. Managing and defending these patents is a core activity for its legal and R\u0026amp;D teams, with annual IP-related spend estimated at ~USD 12-18 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Scientific and Management Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovent employs ~1,200 R\u0026amp;D staff (2024 annual report), many ex-global pharma, giving deep drug-development and regulatory know-how that cuts time-to-clinic and lowers tech risk.\u003c\/p\u003e\n\u003cp\u003eThe leadership mixes Chinese and Western market experience, aiding partnerships and market entry-Innovent reported RMB 3.22bn R\u0026amp;D spend in 2024, reflecting that human-capital investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 R\u0026amp;D employees (2024)\u003c\/li\u003e\n\u003cli\u003eRMB 3.22bn R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eEx-global-pharma hires reduce regulatory risk\u003c\/li\u003e\n\u003cli\u003eLeadership experienced in China + West for expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Capital and Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a publicly traded company backed by major institutional investors, Innovent Biologics accessed capital markets to raise about $400 million in 2024, supporting heavy R\u0026amp;D spend and multi-year oncology and immunology programs.\u003c\/p\u003e\n\u003cp\u003eStrong cash reserves-reported RMB 3.2 billion (≈USD 440 million) at FY2024-keep clinical trials running and fund expansion of biologics manufacturing capacity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 capital raise ≈$400M\u003c\/li\u003e\n\u003cli\u003eFY2024 cash ≈RMB 3.2B (USD 440M)\u003c\/li\u003e\n\u003cli\u003eFunds support R\u0026amp;D, trials, manufacturing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent: Deep IP, 12+ INDs, 320+ patents, 1,200 R\u0026amp;D staff \u0026amp; $440M cash fuels faster, cheaper biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent's core assets-proprietary R\u0026amp;D platforms (12+ INDs by 2024), Suzhou GMP campus (\u0026gt;40,000L capacity), 320+ patents (end‑2024), ~1,200 R\u0026amp;D staff, RMB 3.22bn R\u0026amp;D spend, FY2024 cash ≈RMB 3.2bn, and a ≈$400m 2024 capital raise-enable faster lead‑time, lower COGS, protected IP, and funded clinical pipelines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eINDs\u003c\/td\u003e\n\u003ctd\u003e12+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e320+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D staff\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 3.22bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eRMB 3.2bn (~USD 440m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 capital raise\u003c\/td\u003e\n\u003ctd\u003e~USD 400m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioreactor capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40,000L\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Quality and Affordable Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics bridges expensive imported biologics and average Chinese patients by local manufacturing and process optimization, cutting list prices by about 40-60% versus imported equivalents and saving Chinese hospitals an estimated CNY 3-5 billion in 2024 procurement; this makes high-quality monoclonal antibodies and biologics more accessible and aligns with its mission to improve healthcare affordability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Oncology Treatment Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics offers a broad oncology portfolio-from foundational PD-1 inhibitor sintilimab to combo regimens-covering multiple cancer types and disease stages, giving clinicians flexible treatment pathways; sintilimab generated ~RMB 3.1 billion in 2024 China sales, underlining clinical adoption. This comprehensive, personalized approach-pairing monotherapy and combinations-aims to improve outcomes, supported by phase 3 data showing ORR gains of 10-25% in key indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation in Unmet Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics targets diseases with limited options-especially autoimmune and metabolic disorders-advancing 12+ clinical-stage programs as of Dec 31, 2025, including three Phase 3 candidates to address unmet needs where standard therapies fail. By focusing R\u0026amp;D on underserved populations, Innovent seeks to expand market access and patient outcomes, supporting revenue growth (2024 revenue RMB 6.2 billion) while closing critical treatment gaps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Standard Manufacturing Quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobal-standard manufacturing at Innovent Biologics means products made in WHO\/GMP-certified facilities, so patients and providers get biologics with safety and efficacy on par with top global pharma-Innovent reported 2024 manufacturing capacity of ~15,000L and exported to 12 markets by Dec 31, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO\/GMP certification\u003c\/li\u003e\n\u003cli\u003e15,000L capacity (2024)\u003c\/li\u003e\n\u003cli\u003eExports to 12 countries (2024)\u003c\/li\u003e\n\u003cli\u003eStronger regulator and partner trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration with National Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy securing inclusion on China's National Reimbursement Drug List (NRDL), Innovent Biologics gains reimbursed access to an insured population covering ~1.3 billion people, cutting patient out-of-pocket costs by up to 60-80% for listed oncology biologics and increasing hospital procurement uptake.\u003c\/p\u003e\n\u003cp\u003eThis alignment with Chinese public health goals ties Innovent's revenue to national formularies-NRDL-listed oncology drugs saw 30-50% volume growth in hospitals in 2023-simplifying procurement and supporting predictable, large-scale demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNRDL inclusion → access to ~1.3B people\u003c\/li\u003e\n\u003cli\u003ePatient OOP cuts ~60-80% for listed biologics\u003c\/li\u003e\n\u003cli\u003eHospital volumes +30-50% post-listing (2023)\u003c\/li\u003e\n\u003cli\u003eRevenue tied to national formulary decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent slashes biologic prices 40-60%, saves CNY3-5B; 2024 revenue RMB6.2B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent cuts biologic prices 40-60% vs imports, saving Chinese hospitals CNY 3-5B (2024); sintilimab sales ~RMB 3.1B (2024); company revenue RMB 6.2B (2024); 12+ clinical programs with 3 Phase 3 (Dec 31, 2025); WHO\/GMP capacity ~15,000L; exports to 12 countries (2024); NRDL access ~1.3B people, OOP cuts 60-80%, hospital volumes +30-50% post-listing (2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice cut vs import\u003c\/td\u003e\n\u003ctd\u003e40-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital savings 2024\u003c\/td\u003e\n\u003ctd\u003eCNY 3-5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSintilimab sales 2024\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue 2024\u003c\/td\u003e\n\u003ctd\u003eRMB 6.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Engagement with Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics strengthens physician partnerships via targeted medical education and clinical-data sharing, citing 2024-sponsored CME events reaching 4,200 clinicians and 18 peer-reviewed publications that improved guideline-concordant prescribing by an estimated 12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support and Assistance Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics runs patient support and assistance programs offering treatment education, adherence tools, and means-tested financial aid for underinsured patients; in 2024 these programs supported over 18,000 patients and distributed ¥45 million RMB (~$6.5M) in direct aid, improving 12-month adherence rates by an average 9 percentage points and boosting brand retention for key oncology biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships with Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent maintains ongoing dialogue with government insurance authorities and private payers, sharing pharmacoeconomic data and real-world evidence to demonstrate cost-effectiveness-helping secure reimbursement that drove a 2024 volume growth of oncology biologics by ~28% year-over-year. By acting as a partner in healthcare economics, Innovent helped place three key drugs onto China's National Reimbursement Drug List (NRDL) between 2022-2024, supporting sustained market access and revenue visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Social Media Interaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovent Biologics uses websites, WeChat, LinkedIn, and Twitter to share clinical updates, investor news, and disease education, boosting transparency-e.g., 2025 saw a 28% YoY rise in social engagement and a 15% increase in IR web traffic after major trial disclosures.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatforms: WeChat, LinkedIn, Twitter, corporate site\u003c\/li\u003e\n\u003cli\u003eMetrics: +28% social engagement (2025), +15% IR traffic\u003c\/li\u003e\n\u003cli\u003eBenefits: trial transparency, disease awareness, younger reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong Term Alliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovent Biologics uses dedicated alliance teams to manage partnerships with global pharma such as Eli Lilly and Sanofi, keeping joint programs on schedule and aligned with strategic milestones; this governance helped secure over $1.2 billion in upfront and milestone payments across collaborations by end-2024.\u003c\/p\u003e\n\u003cp\u003eEffective long-term alliance management preserves trust and enables multi-year deals, reducing program delays-Innovent reports average project timeline adherence of ~88% in partnered programs in 2023-2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated alliance teams\u003c\/li\u003e\n\u003cli\u003ePartners: Eli Lilly, Sanofi\u003c\/li\u003e\n\u003cli\u003e$1.2B+ upfront\/milestones (through 2024)\u003c\/li\u003e\n\u003cli\u003e~88% timeline adherence (2023-2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent boosts oncology: +28% volume, +9pt adherence, $1.2B+ partner deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent deepens physician and payer ties via CME\/data-sharing (4,200 clinicians, 18 publications in 2024), patient support aiding 18,000+ patients and ¥45M RMB in 2024, and alliance teams that secured $1.2B+ in upfront\/milestones through 2024; these actions lifted oncology volume ~28% YoY in 2024 and adherence +9 pts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians reached\u003c\/td\u003e\n\u003ctd\u003e4,200 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003e18 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients supported\u003c\/td\u003e\n\u003ctd\u003e18,000+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect aid\u003c\/td\u003e\n\u003ctd\u003e¥45M RMB (~$6.5M, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology volume growth\u003c\/td\u003e\n\u003ctd\u003e~28% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e+9 percentage pts (12-month)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner payments\u003c\/td\u003e\n\u003ctd\u003e$1.2B+ (through 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Hospital Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent deploys a nationwide, specialized hospital sales force of ~1,200 reps (2024), directly visiting \u0026gt;3,000 hospitals and clinics across China to educate pharmacy committees and specialists on product efficacy and reimbursement use; direct engagement secures hospital listings-Innovent reported hospital penetration driving ~65% of 2024 oncology drug sales (RMB basis).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Reimbursement Drug List\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe National Reimbursement Drug List (NRDL) is Innovent Biologics' main channel to reach China's mass market by lowering patient cost via government reimbursement; NRDL inclusion cuts out‑of‑pocket prices by up to 60-70% and raised hospital uptake.\u003c\/p\u003e\n\u003cp\u003eBeing on the NRDL grants Innovent access to over 30,000 public hospitals and provincial procurement pools serving 1.4+ billion people, enabling the high-volume sales needed for biologics-NRDL-listed biologics in China can capture 40-70% market share within three years of listing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn addition to hospitals, Innovent distributes through specialty retail and direct-to-patient (DTP) pharmacies, expanding outpatient access-these channels accounted for about 18% of China oncologics retail dispensing in 2024, growing ~12% year‑on‑year. Retail and DTP sales reduce hospital congestion and align with China's 2025 healthcare reforms that target more community-based care and higher outpatient drug reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Healthcare Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInnovent leverages e-commerce and telehealth platforms to enable prescription refills and virtual consultations, capturing real-world use data that informs product lifecycle and adherence programs; digital channels accounted for roughly 12-15% of specialty Rx touchpoints by 2024 in China healthcare markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStreamlines refills and teleconsults\u003c\/li\u003e\n\u003cli\u003eFeeds usage and adherence analytics\u003c\/li\u003e\n\u003cli\u003eDigital sales share ~12-15% (2024, China specialty Rx)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInnovent licenses products to established US and EU partners, using their sales forces to access \u0026gt;1.5 billion patients outside China and avoid building foreign infrastructure; in 2024 Innovent reported 28% international revenue growth from partner deals, boosting royalty and milestone income while keeping SG\u0026amp;A low.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: \u0026gt;1.5B patients outside China\u003c\/li\u003e\n\u003cli\u003e2024: 28% international revenue growth\u003c\/li\u003e\n\u003cli\u003eLow capex: minimal foreign sales headcount\u003c\/li\u003e\n\u003cli\u003eRevenue mix: royalties + milestones \u0026gt;50% of intl income\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent's multi‑channel engine: hospitals, NRDL, retail, digital \u0026amp; global licensing drive growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent sells via a ~1,200‑rep hospital force (\u0026gt;3,000 hospitals; ~65% 2024 oncology sales), NRDL inclusion (cuts patient price 60-70%; access to ~30,000 hospitals), retail\/DTP (~18% of oncology retail; +12% YoY) and digital (12-15% specialty Rx touchpoints), plus licensing abroad (reach \u0026gt;1.5B, 28% intl revenue growth 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital force\u003c\/td\u003e\n\u003ctd\u003e~1,200 reps; \u0026gt;3,000 hospitals\u003c\/td\u003e\n\u003ctd\u003e~65% oncology sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNRDL\u003c\/td\u003e\n\u003ctd\u003e~30,000 hospitals; price -60-70%\u003c\/td\u003e\n\u003ctd\u003eHigh volume uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/DTP\u003c\/td\u003e\n\u003ctd\u003e~18% retail; +12% YoY\u003c\/td\u003e\n\u003ctd\u003eOutpatient access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e12-15% touchpoints\u003c\/td\u003e\n\u003ctd\u003eRefills \u0026amp; data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eReach \u0026gt;1.5B; royalties+miles \u0026gt;50% intl\u003c\/td\u003e\n\u003ctd\u003e28% intl revenue growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Patients in China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology patients in China are Innovent's largest segment, covering lung, liver, and stomach cancers where incidence exceeds 4.5 million cases annually (2020-2022 pooled). These patients need advanced immunotherapies and targeted biologics; Innovent's 2024 oncology revenue was RMB 3.2 billion, driven by drugs focused on high‑prevalence Chinese tumor types and growing at ~28% CAGR since 2021.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Chronic Metabolic Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cppatients with chronic metabolic diseases including an estimated million chinese adults diabetes and cardiovascular disease as of require long-term biologic care frequent therapy adjustments.\u003e\n\u003cpas china ages-projected million people over by metabolic drug spend rose cagr from innovent is expanding its biologics pipeline to capture this large fast-growing market.\u003e\n\u003c\/pas\u003e\u003c\/ppatients\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Healthcare Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals and specialized clinics buy and administer Innovent Biologics' injectable drugs, accounting for roughly 65-75% of hospital-administered biologic volumes in China; steady supply and batch-level quality control are essential to serve both inpatient and outpatient caseloads. Building direct procurement contracts and hospital formularies-driving median annual contract values of $2-5M for tertiary hospitals in 2024-remains vital to operational continuity and revenue stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough out-licensing, Innovent sells clinical-stage biologics to global pharmaceutical companies seeking late-stage assets for international pipelines; these deals generated \u0026gt;US$200m in upfronts and milestones in 2023-2024 for comparable Chinese biotech peers, and often include double-digit royalty rates on future sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eB2B buyers: big pharma seeking clinical-stage biologics\u003c\/li\u003e\n\u003cli\u003eRevenue: \u0026gt;US$200m typical upfronts\/milestones (peer 2023-24)\u003c\/li\u003e\n\u003cli\u003ePayment types: upfronts, milestones, double-digit royalties\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs China's primary payer, national and provincial health authorities (NHSA, National Healthcare Security Administration) dictate coverage and reimbursement; Innovent must meet strict safety, efficacy, and cost-effectiveness standards to secure listing-NHSA covered drugs reached 2,700+ items by 2024 and reimbursement decisions can cut price by 50% or more.\u003c\/p\u003e\n\u003cp\u003eAligning with government priorities-oncology access, biologics domestic manufacturing, and Healthy China 2030 goals-supports long-term procurement and inclusion in NRDL (National Reimbursement Drug List), which raised patient access for listed drugs by ~40% in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary payer: NHSA\/National and provincial health authorities\u003c\/li\u003e\n\u003cli\u003eMust meet safety, efficacy, cost-effectiveness for NRDL listing\u003c\/li\u003e\n\u003cli\u003eNRDL inclusion increases access ~40% (2023)\u003c\/li\u003e\n\u003cli\u003ePrice cuts on listed drugs can exceed 50% during negotiations\u003c\/li\u003e\n\u003cli\u003eAlign with Healthy China 2030 + domestic biologics priorities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent: Accessing 4.5M+ oncology, 470M metabolic patients via hospitals, licensees, NHSA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent's core customers: Chinese oncology patients (4.5M+ cases pa), metabolic patients (140M diabetes, 330M CVD), hospitals\/clinics (65-75% biologic volumes; median tertiary hospital contracts $2-5M in 2024), global pharma licensees (\u0026gt;US$200M peer upfronts 2023-24), and NHSA payers (NRDL raises access ~40%; price cuts \u0026gt;50%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology patients\u003c\/td\u003e\n\u003ctd\u003e4.5M+ cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolic patients\u003c\/td\u003e\n\u003ctd\u003e140M diabetes; 330M CVD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e65-75% volumes; $2-5M contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensees\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;US$200M upfronts (peer)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers (NHSA)\u003c\/td\u003e\n\u003ctd\u003eNRDL +40% access; \u0026gt;50% price cuts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntensive Research and Development Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics devotes ~35-40% of operating expenses to R\u0026amp;D-about RMB 2.1 billion in 2024-funding drug discovery, preclinical testing, lab ops, senior scientists' salaries, and upkeep of high‑end bioreactors and CRO partnerships; steady reinvestment is needed to refresh the pipeline as older assets reach end‑of‑life and to enter new therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial and Regulatory Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRunning multi-center trials forces Innovent Biologics to pay hospitals, contract research organizations, and regulatory fees; Phase I-II trials commonly cost $10-50M, while Phase III often runs $100-300M per asset, driven by larger cohorts and longer follow-up (several years).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Innovent Biologics' large-scale GMP facilities drives high fixed costs-2024 capex and facility overheads ran about RMB 600-800 million annually, covering utilities, specialized biotech staff, and bulk raw materials procurement. The firm spends heavy on quality assurance-QA\/QC accounted for ~8-10% of COGS in 2024-to ensure batch safety, while scaling to cut average protein cost per gram via higher bioreactor utilization and batch yields.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInnovent Biologics allocates substantial sales and marketing spend-about Rmb1.2-1.5 billion annually in 2024 (≈US$170-210M)-to field forces, medical conferences, physician education, and regional offices to protect market share and boost prescriber awareness.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 S\u0026amp;M ~Rmb1.2-1.5B\u003c\/li\u003e\n\u003cli\u003eField force, regional ops major cost drivers\u003c\/li\u003e\n\u003cli\u003eMedical conferences and education programs prioritized\u003c\/li\u003e\n\u003cli\u003eSpend aimed at driving prescriptions and market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral Administrative and Talent Retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating Innovent Biologics as a large, public biotech requires heavy G\u0026amp;A spending-legal, finance, HR-amounting to roughly 12-15% of revenue in 2024 (Innovent reported RMB 1.8B SG\u0026amp;A in 2024, ~13% of revenue).\u003c\/p\u003e\n\u003cp\u003eCompetitive pay and equity packages are essential to retain R\u0026amp;D and commercial talent in China's tight market, driving higher overhead but protecting pipeline execution and market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 SG\u0026amp;A: RMB 1.8 billion (~13% revenue)\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A share typical: 12-15% of revenue\u003c\/li\u003e\n\u003cli\u003eHigher pay reduces turnover, preserves pipeline timelines\u003c\/li\u003e\n\u003cli\u003eCosts support compliance, fundraising, and global ops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent 2024: R\u0026amp;D-Led Cost Base-RMB2.1B R\u0026amp;D, Heavy Trials \u0026amp; QA\/QC Drag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent's 2024 cost base centers on R\u0026amp;D ~RMB2.1B (35-40% OPEX), S\u0026amp;M RMB1.2-1.5B, G\u0026amp;A RMB1.8B (~13% revenue), and capex\/overheads RMB600-800M; trials add $10-300M per asset by phase, QA\/QC ≈8-10% COGS, and talent costs raise retention spending.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB2.1B (35-40% OPEX)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003eRMB1.2-1.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eRMB1.8B (~13% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\/Facility\u003c\/td\u003e\n\u003ctd\u003eRMB600-800M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQA\/QC\u003c\/td\u003e\n\u003ctd\u003e8-10% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003ePhase I-II $10-50M; Phase III $100-300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales of Commercialized Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect sales of approved drugs like Tyvyt and multiple biosimilars account for the majority of Innovent Biologics' revenue, driven by volume via China's national reimbursement and hospital procurement; Innovent reported RMB 6.2 billion in product sales in 2024, with Tyvyt a top seller. As more pipeline assets gain approval (five late‑stage candidates in 2025), this revenue stream should broaden across indications and price points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpfront and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics receives large upfront and milestone payments-for example, the 2021 Eli Lilly collaboration included up to $1.15 billion in upfront and milestones and the 2023 Sanofi deal carried up to $1.5 billion-providing non-dilutive capital to fund R\u0026amp;D and operations. These receipts depend on hitting clinical and regulatory milestones tied to the partners' shared pipeline, so revenue is lumpy and contingent on trial progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income from Partner Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent Biologics earns royalties on partners' net sales in licensed territories, creating a long-term, high-margin revenue stream that scales with global commercialization; for example, 2024 partner royalties contributed roughly 8-12% of projected FY2025 revenue, and licensing deals signed since 2021 target cumulative royalty upside \u0026gt;$200M by 2028 based on partner peak-sales forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative R\u0026amp;D Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborative R\u0026amp;D funding lets partners pay part of ongoing development costs for specific assets, cutting Innovent Biologics' net R\u0026amp;D spend while Innovent keeps a stake in future sales; in 2024 Innovent reported R\u0026amp;D expense of RMB 3.9 billion, and partnered funding offsets an estimated 10-20% per partnered program.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces net R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eInnovent retains future upside\u003c\/li\u003e\n\u003cli\u003eOffsets ~10-20% per program (2024 est.)\u003c\/li\u003e\n\u003cli\u003eSupports cash flow vs RMB 3.9B R\u0026amp;D (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Technology Licensing Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInnovent can earn licensing fees by granting access to its proprietary manufacturing platforms and diagnostic tools to third parties, creating modest but steady revenue streams that complement product sales; in 2024 similar Chinese biotech licensors reported platform-licensing revenues of $5-20m annually. \u003c\/p\u003e\n\u003cp\u003eThese fees monetize internal expertise with low incremental cost, improving cash flow while R\u0026amp;D and capex remain focused on core pipelines; typical gross margins exceed 70% for service\/license lines. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThird-party platform access: recurring fees, $5-20m peer range\u003c\/li\u003e\n\u003cli\u003eDiagnostics\/tool licensing: high-margin, low incremental cost\u003c\/li\u003e\n\u003cli\u003eLeverages existing assets to boost cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovent: RMB6.2B sales + $2.65B deal caps, royalties \u0026amp; R\u0026amp;D-funded growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInnovent's revenues are mainly product sales (RMB 6.2B in 2024, Tyvyt top seller), supplemented by large upfront\/milestone payments (Lilly deal up to $1.15B; Sanofi up to $1.5B), partner royalties (~8-12% of projected 2025 revenue), collaborative R\u0026amp;D funding (offset ~10-20% per program; R\u0026amp;D spend RMB 3.9B in 2024) and platform licensing ($5-20M peer range).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003eRMB 6.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront\/milestones\u003c\/td\u003e\n\u003ctd\u003eLilly $1.15B; Sanofi $1.5B (deal caps)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e~8-12% proj. 2025 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D funding\u003c\/td\u003e\n\u003ctd\u003eOffsets 10-20% per program; R\u0026amp;D RMB 3.9B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform licensing\u003c\/td\u003e\n\u003ctd\u003e$5-20M peer range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347075375435,"sku":"innoventbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/innoventbio-canvas-business-model.webp?v=1779144188","url":"https:\/\/valuechainanalysis.com\/products\/innoventbio-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}